Zhaoke Ophthalmology Ltd.
HHKEX:66221.90
HKD
-0.04
(-2.06%)
ISIN
KYG989M51017
CUSIP
G989M5101
Return %
Stock
S&P 500
1Y
-37.29
14.39
3Y
-52.50
81.42
5Y
-73.54
68.62
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Xiao Yi Li
- Full Time Employees
- 276
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 1 Meide 3rd Road Guangzhou GD China 511462
- IPO Date
- Apr 29, 2021
- Website
- zkoph.com
- Similar Companies
- Business
- Zhaoke Ophthalmology Limited (SEHK: 6622) is a Cayman Islands-incorporated ophthalmic pharmaceutical company founded in 2017 and headquartered in Nansha, Guangzhou, People's Republic of China, that engages in the research, development, manufacturing, and commercialization of therapies addressing major eye diseases across the anterior and posterior segments, including dry eye disease (DED), myopia, presbyopia, wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and glaucoma. The company maintains a fully integrated platform with a state-of-the-art production facility in Nansha and offers a comprehensive pipeline of 13 innovative drugs and 12 generic drugs; flagship innovative assets include Cyclosporine A (CsA) Ophthalmic Gel and NVK-002 (Atropine Sulfate Eye Drops) for DED under NDA review with NMPA, TAB014 (Bevacizumab Intravitreal Injection) in Phase III for wAMD, BRIMOCHOL™ PF in preparation for Phase III for presbyopia, and ZKY001 for corneal epithelial defects, alongside generic offerings targeting broader patient access. Zhaoke Ophthalmology primarily serves the Chinese market with expansion into ASEAN, South Korea, Hong Kong, the GCC, Middle East, and Indonesia through strategic partnerships, including its second collaboration with PT Ferron in November 2025 for BRIMOCHOL™ PF commercialization in Indonesia, agreements with Jamjoom Pharmaceuticals in June 2025 for CsA Ophthalmic Gel in the Middle East, Lunatus in March 2025 for BRIMOCHOL™ PF in the GCC, Somerset Therapeutics and FAREVA in June-July 2025 for manufacturing and global supply, and Seefunge in early 2025 for joint product launches; these alliances support its global growth strategy while advancing near-term commercialization goals.